D. Larrey

发表

Presence of functional cytochrome P‐450 on isolated rat hepatocyte plasma membrane

P. Beaune, D. Pessayre, G. Feldmann, 1990, Hepatology.

Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II.

D. Pessayre, B. Fromenty, A. Berson, 1990, The Journal of pharmacology and experimental therapeutics.

Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro

J. Pawlotsky, D. Dhumeaux, J. Coste, 2002, Journal of Virology.

In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus.

C. Sureau, J. Coste, P. Maurel, 1998, The Journal of general virology.

Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease.

D. Pessayre, C. Degott, G. Feldmann, 1990, Journal of clinical gastroenterology.

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Jennifer G. Robinson, J. D. Jordan, G. Molenberghs, 2016, Journal of the American Heart Association.

Memoirs of military surgery, and campaigns of the French armies

D. Larrey, 1814 .

Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans.

D. Pessayre, J. Belghiti, J. Benhamou, 1982, Biochemical pharmacology.

Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis.

D. Pessayre, B. Fromenty, A. Berson, 1994, Journal of hepatology.

Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes.

P. Beaune, F. Guengerich, L. Kaminsky, 1983, Biochemistry.

Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.

F. Guengerich, G. Wilkinson, D. Larrey, 1984, Biochemistry.

Drug‐induced prolonged cholestasis in adults: A histological semiquantitative study demonstrating progressive ductopenia

C. Degott, G. Feldmann, J. Benhamou, 1992, Hepatology.

Use of human hepatocytes to investigate HCV infection.

P. Maurel, A. Sa-cunha, Sylvain Laporte, 2010, Methods in molecular biology.

The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus.

D. Harats, F. Malavasi, C. Fournier-Wirth, 2007, Journal of hepatology.

Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P450.

D. Pessayre, J. Belghiti, P. Maurel, 1990, Biochemical pharmacology.

Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450.

D. Pessayre, A. Berson, P. Lettéron, 1989, Biochemical pharmacology.

Methoxsalen decreases the metabolic activation and prevents the hepatotoxicity and nephrotoxicity of chloroform in mice.

G. Labbe, D. Pessayre, C. Degott, 1987, Toxicology and applied pharmacology.

The drug methoxsalen, a suicide substrate for cytochrome P-450, decreases the metabolic activation, and prevents the hepatotoxicity, of carbon tetrachloride in mice.

G. Labbe, D. Pessayre, C. Degott, 1987, Biochemical pharmacology.

Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives.

D. Pessayre, J. Belghiti, P. Lettéron, 1987, Biochemical pharmacology.

Formation of an inactive cytochrome P-450Fe(II)-metabolite complex after administration of amiodarone in rats, mice and hamsters.

D. Pessayre, P. Lettéron, V. Descatoire, 1986, Biochemical pharmacology.

Regulation of renal cytochrome P-450. Effects of two-thirds hepatectomy, cholestasis, biliary cirrhosis and post-necrotic cirrhosis on hepatic and renal microsomal enzymes.

D. Pessayre, C. Degott, C. Funck-Brentano, 1985, Biochemical pharmacology.

Hepatotoxicity of trichloroethylene-carbon tetrachloride mixtures in rats. A possible consequence of the potentiation by trichloroethylene of carbon tetrachloride-induced lipid peroxidation and liver lesions.

D. Pessayre, M. Delaforge, C. Degott, 1982, Gastroenterology.

Genetic predisposition to drug hepatotoxicity: Role in hepatitis caused by amineptine, a tricyclic antidepressant

D. Pessayre, A. Berson, P. Dansette, 1989, Hepatology.

Hepatotoxicity of Psychotropic Drugs and Drugs of Abuse

D. Larrey, M. Ripault, 2013 .

Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant.

G. Labbe, D. Pessayre, B. Fromenty, 1990, Biochemical pharmacology.

Hepatic Findings in Long-Term Clinical Trials of Ximelagatran

William M. Lee, William M Lee, James H. Lewis, 2005, Drug safety.

Inactivation and induction of cytochrome P-450 by various psoralen derivatives in rats.

D. Pessayre, P. Lettéron, V. Descatoire, 1986, The Journal of pharmacology and experimental therapeutics.

Chronic active hepatitis caused by benzarone.

D. Pessayre, C. Degott, J. Benhamou, 1987, Journal of hepatology.

Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER).

C. Cannon, D. Blom, James A. Underberg, 2020, Journal of clinical lipidology.

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia.

D. Gaudet, D. Rader, R. Hegele, 2017, Circulation.

Lomitapide Observational Worldwide Evaluation Registry (LOWER): One-Year Data†

D. Blom, L. Bloedon, James A. Underberg, 2015 .

Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy.

D. Pessayre, L. Bélec, R. Gherardi, 1989, British journal of clinical pharmacology.

Metoprolol-induced hepatitis: rechallenge and drug oxidation phenotyping.

D. Pessayre, C. Degott, J. Benhamou, 1988, Annals of internal medicine.

Interleukin 1β inhibits CAR‐induced expression of hepatic genes involved in drug and bilirubin clearance

J. Pascussi, J. Saric, E. Assenat, 2004, Hepatology.

Alcoholic-like liver lesions induced by nifedipine.

C. Degott, J. Benhamou, C. Vissuzaine, 1989, Journal of hepatology.

Exacerbation of multiple sclerosis after the administration of recombinant human interferon alfa.

P. Marcellin, D. Pessayre, J. Benhamou, 1989, JAMA.

Peliosis hepatis induced by 6-thioguanine administration.

D. Pessayre, D. Valla, C. Degott, 1988, Gut.

Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin.

P. Beaune, F. Guengerich, R. Schnellmann, 1984, Drug metabolism and disposition: the biological fate of chemicals.

Effects of methoxsalen on the metabolism of acetaminophen in humans.

G. Labbe, D. Pessayre, J. Belghiti, 1987, Biochemical pharmacology.

Drug interactions and hepatitis produced by some macrolide antibiotics.

D. Pessayre, C. Funck-Brentano, J. Benhamou, 1985, The Journal of antimicrobial chemotherapy.

Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides.

G. Labbe, D. Pessayre, P. Lettéron, 1989, The Journal of pharmacology and experimental therapeutics.

Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences

J. Pascussi, E. Assenat, J. Pascussi, 2004, Xenobiotica; the fate of foreign compounds in biological systems.

Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic

G. Labbe, D. Pessayre, C. Degott, 1988, Hepatology.

Presence of covalently bound metabolites on rat hepatocyte plasma membrane proteins after administration of isaxonine, a drug leading to immunoallergic hepatitis in man

D. Pessayre, P. Lettéron, V. Descatoire, 1989, Hepatology.

Prolonged cholestasis after troleandomycin-induced acute hepatitis.

G. Danan, D. Pessayre, C. Degott, 1987, Journal of hepatology.

Prolonged cholestasis after ajmaline-induced acute hepatitis.

D. Pessayre, C. Degott, G. Feldmann, 1986, Journal of hepatology.

Effects of erythromycin on hepatic drug-metabolizing enzymes in humans.

D. Pessayre, C. Funck-Brentano, G. Babany, 1983, Biochemical pharmacology.

Inactivation of cytochrome P-450 by the drug methoxsalen.

D. Pessayre, H. Fouin-Fortunet, P. Lettéron, 1986, The Journal of pharmacology and experimental therapeutics.

Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate.

D. Pessayre, Y. Horsmans, D. Larrey, 1994, Journal of hepatology.

Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients.

F. Iglicki, A. Berson, H. Fouin-Fortunet, 1989, Journal of hepatology.

Amitriptyline-induced prolonged cholestasis.

D. Pessayre, C. Degott, G. Feldmann, 1988, Gastroenterology.

[Genetic polymorphism of the hepatic metabolism of drugs].

D. Pessayre, J. Benhamou, D. Larrey, 1985, Gastroenterologie clinique et biologique.

Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis.

P. Beaune, D. Pessayre, F. Guengerich, 1990, The Journal of clinical investigation.

Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug.

P. Beaune, A. Guillouzo, M. Bourdi, 1992, Molecular pharmacology.

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

C. Trautwein, G. Gerken, A. Tran, 2010 .

Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug.

G. Labbe, D. Pessayre, C. Degott, 1987, The Journal of pharmacology and experimental therapeutics.

Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids.

G. Labbe, D. Pessayre, B. Fromenty, 1990, The Journal of pharmacology and experimental therapeutics.

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.

Z. Fayad, D. Blom, James A. Underberg, 2016, Journal of clinical lipidology.

Serum-Derived Hepatitis C Virus Infection of Primary Human Hepatocytes Is Tetraspanin CD81 Dependent

J. Dubuisson, J. Pascussi, J. McKeating, 2007, Journal of Virology.

Recurrent jaundice caused by recurrent hyperemesis gravidarum.

G. Danan, C. Degott, G. Feldmann, 1984, Gut.

Cross hepatotoxicity between tricyclic antidepressants.

G. Danan, D. Pessayre, J. Benhamou, 1986, Gut.

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia

M. Arca, D. Larrey, L. D’Erasmo, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population.

D. Pessayre, A. Berson, Y. Horsmans, 1991, British journal of clinical pharmacology.

Idiopathic biliary ductopenia in adults: a report of five cases.

D. Dhumeaux, E. Zafrani, J. Benhamou, 1990, Gastroenterology.

Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats.

D. Pessayre, D. Larrey, M. Tinel, 1983, Biochemical pharmacology.

Amodiaquine-lnduced Hepatitis: A Report of Seven Cases

D. Pessayre, G. Feldmann, J. Benhamou, 1986 .

Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.

J. Lewis, D. Larrey, L. Frison, 2008, International journal of clinical pharmacology and therapeutics.

Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.

D. Pessayre, P. Lettéron, G. Amouyal, 1989, British journal of clinical pharmacology.

Polymorphism of dextromethorphan oxidation in a French population.

G. Labbe, D. Pessayre, A. Berson, 1987, British journal of clinical pharmacology.

Clearance by the Liver: Current Concepts in Understanding the Hepatic Disposition of Drugs

R. Branch, D. Larrey, 1983, Seminars in liver disease.

Propranolol does not further decrease the clearance of antipyrine in patients with alcoholic cirrhosis.

D. Pessayre, D. Lebrec, D. Larrey, 1983, Clinical science.

Fulminant hepatitis after lisinopril administration.

D. Pessayre, C. Degott, J. Bernuau, 1990, Gastroenterology.

Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione.

D. Pessayre, C. Funck-Brentano, G. Babany, 1983, The Journal of pharmacology and experimental therapeutics.

Clotiazepam-induced acute hepatitis.

D. Pessayre, C. Degott, J. Benhamou, 1989, Journal of hepatology.

PYRAZINAMIDE FULMINANT HEPATITIS: AN OLD HEPATOTOXIN STRIKES AGAIN

D. Pessayre, J. Benhamou, D. Larrey, 1981, The Lancet.

Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes.

D. Pessayre, Y. Horsmans, P. Lettéron, 1991, Xenobiotica; the fate of foreign compounds in biological systems.

Tianeptine, a new tricyclic antidepressant metabolized by beta-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice.

G. Labbe, D. Pessayre, B. Fromenty, 1989, Biochemical pharmacology.

Prolonged cholestasis after cyproheptadine-induced acute hepatitis.

D. Pessayre, C. Degott, J. Benhamou, 1987, Journal of clinical gastroenterology.

[Hepatitis caused by cyproheptadine (Periactine). A case and review of the literature].

D. Pessayre, A. Berson, J. Benhamou, 1988, Gastroenterologie clinique et biologique.

Metabolic activation of the tricyclic antidepressant amineptine--I. Cytochrome P-450-mediated in vitro covalent binding.

D. Pessayre, P. Lettéron, V. Descatoire, 1987, Biochemical pharmacology.

Metabolic activation of the tricyclic antidepressant amineptine--II. Protective role of glutathione against in vitro and in vivo covalent binding.

D. Pessayre, C. Degott, P. Lettéron, 1987, Biochemical pharmacology.

Suicide inactivation of cytochrome P-450 by methoxsalen. Evidence for the covalent binding of a reactive intermediate to the protein moiety.

P. Beaune, G. Labbe, D. Pessayre, 1989, The Journal of pharmacology and experimental therapeutics.

Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice.

G. Labbe, D. Pessayre, C. Degott, 1988, The Journal of pharmacology and experimental therapeutics.

Effects of pregnancy on the toxicity and metabolism of acetaminophen in mice.

D. Pessayre, C. Degott, P. Lettéron, 1986, The Journal of pharmacology and experimental therapeutics.

Amodiaquine-induced hepatitis. A report of seven cases.

G. Feldmann, J. Benhamou, A. Castot, 1986, Annals of internal medicine.

Amodiaquine-induced fulminant hepatitis.

D. Pessayre, C. Degott, B. Campillo, 1988, Journal of hepatology.

Metabolic activation of the antidepressant tianeptine. II. In vivo covalent binding and toxicological studies at sublethal doses.

G. Labbe, D. Pessayre, C. Degott, 1989, Biochemical Pharmacology.

Metabolic activation of the antidepressant tianeptine. I. Cytochrome P-450-mediated in vitro covalent binding.

G. Labbe, D. Pessayre, P. Maurel, 1989, Biochemical pharmacology.

Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450.

D. Pessayre, J. Belghiti, G. Amouyal, 1987, Biochemical pharmacology.

Interleukin 1β inhibits CAR‐induced expression of hepatic genes involved in drug and bilirubin clearance

J. Pascussi, J. Saric, E. Assenat, 2004 .

Bakken Lecture : The brain , the heart , and therapeutic hypothermia

P. Safar, D. Larrey, 2009 .

Presence of functional cytochrome P-450 on isolated rat hepatocyte plasma membrane.

P. Beaune, D. Pessayre, G. Feldmann, 1990, Hepatology.

[Tricyclic structure of drugs and hepatotoxicity].

D. Pessayre, J. Benhamou, D. Larrey, 1987, Gastroenterologie clinique et biologique.

Carbamazepine-induced acute cholangitis

D. Pessayre, C. Degott, A. Hadengue, 1987, Digestive Diseases and Sciences.

Hepatotoxicity of herbal remedies.

D. Larrey, D. Larrey, 1997, Journal of hepatology.

Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases.

D. Larrey, J. Benhamou, A. Micaleff, 1992, Gut.

[Hepatitis probably caused by Plethoryl. Apropos of 7 cases].

D. Pessayre, C. Degott, A. Berson, 1988, Gastroentérologie Clinique et Biologique.

Genetic predisposition to drug-induced hepatotoxicity.

D. Larrey, G. Pageaux, D. Larrey, 1997, Journal of hepatology.

Hepatotoxicity of Herbal Remedies and Mushrooms

D. Larrey, G. Pageaux, D. Larrey, 1995, Seminars in liver disease.

RE: Praluent (Alirocumab)-Induced Renal Injury

D. Waters, R. Rosenson, D. Larrey, 2017, Journal of pharmacy practice.

(Alirocumab)-Induced Renal Injury.

D. Larrey, 2018 .

Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Comparison with troleandomycin.

D. Pessayre, V. Descatoire, D. Larrey, 1982, The Journal of pharmacology and experimental therapeutics.